Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II
NCT ID: NCT01304238
Last Updated: 2017-07-06
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
195 participants
OBSERVATIONAL
2009-02-28
2010-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.
NCT06066762
A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome
NCT00787332
Argatroban Versus Lepirudin in Critically Ill Patients
NCT00798525
Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical
NCT00748839
Evaluating the Presence of Blood Clots in People With Heparin-Induced Thrombocytopenia (HIT) (The HOT Study)
NCT00594685
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
lepirudin
lepirudin treated subjects
lepirudin
lepirudin
danaparoid
danaparoid treated subjects
danaparoid
danaparoid
argatroban
argatroban treated subjects
argatroban
argatroban
fondaparinux
fondaparinux treated subjects
fondaparinux
fondaparinux
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lepirudin
lepirudin
danaparoid
danaparoid
argatroban
argatroban
fondaparinux
fondaparinux
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treatment of HIT with Lepirudin, Danaparoid, Argatroban or Fondaparinux
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
References
Explore related publications, articles, or registry entries linked to this study.
Schindewolf M, Steindl J, Beyer-Westendorf J, Schellong S, Dohmen PM, Brachmann J, Madlener K, Potzsch B, Klamroth R, Hankowitz J, Banik N, Eberle S, Muller MM, Kropff S, Lindhoff-Last E. Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia. J Am Coll Cardiol. 2017 Nov 28;70(21):2636-2648. doi: 10.1016/j.jacc.2017.09.1099.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
108745
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.